All In Biotech

Drug Trial Radar · NCT00098306

Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects.

Last checked: Nov 20, 2026Latest source record: Apr 27, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 601 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

601

Actual

Start

Nov 2004

Primary completion

Apr 2007

Study completion Apr 2011

Sponsor

Lead sponsor
ViiV HealthcareGSK (GSK)
Sponsor type
Industry
Collaborators
Pfizer
First posted
Dec 7, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Maraviroc (UK-427,857), a selective and reversible CCR5 coreceptor antagonist, has been shown to be active in vitro against a wide range of clinical isolates (including those resistant to existing classes). In HIV-1 infected patients, maraviroc (UK-427,857) given as monotherapy for 10 days reduced HIV-1 viral load by up to 1.6 log, consistent with currently available agents. Safety and toleration have been studied in over 400 subjects for up to 28 days at 300 mg twice daily. No significant effects were seen on the QTc interval. The purpose of this study is to evaluate the antiretroviral activity of maraviroc (UK-427,857) in HIV infected, treatment experienced patients who are failing their current antiretroviral regimen and are infected with R5-tropic virus exclusively. This study will involve more than 100 centers from the US and Canada to achieve a total randomized subject population of 500 subjects. Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy \[OBT (3-6 drugs based on treatment history and resistance testing)\] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone. The study will enroll over approximately a 9 month period with 48 weeks of treatment. This may be extended for an additional year depending on the results at 48 weeks. Physical examinations will be performed at study entry, weeks 4, 8, 12, 16, 20, 24, 32, 40, and 48. Blood samples will also be taken at study entry, weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, and 48. Additionally, blood samples will be drawn twice, at least 30 minutes apart, at weeks 2 and 24 for maraviroc (UK-427,857) pharmacokinetic analysis. As part of this clinical study a blood sample will also be taken for non-anonymized pharmacogenetic analysis. Patients will undergo a 12-lead electrocardiogram at study entry, weeks 24 and 48.

Conditions

  • HIV Infections

Interventions

  • Maraviroc (UK-427,857)Drug

    Maraviroc was given either once or twice per day with the dose adjusted according to the optimized background therapy

  • Optimized Background TherapyDrug

    Maraviroc was given either once or twice per day with the dose adjusted according to the optimized background therapy

  • Optimized Background TherapyDrug

    Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy \[OBT (3-6 drugs based on treatment history and resistance testing)\] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.

  • PlaceboDrug

    Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy \[OBT (3-6 drugs based on treatment history and resistance testing)\] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.

  • Optimized Background TherapyDrug

    Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy \[OBT (3-6 drugs based on treatment history and resistance testing)\] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone. The study will enroll over approximately a 9 month period with 48 weeks of treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Log 10-transformed Human Immunodeficiency Virus Ribonucleic Acid (HIV-1 RNA) Levels at BaselineTime frame: Baseline
  2. Change From Baseline in Log 10-transformed HIV-1 RNA Levels at Week 24Time frame: Baseline and Week 24
  3. Change From Baseline in Log 10-transformed HIV-1 RNA Levels at Week 48Time frame: Baseline and Week 48

Locations

22 sites in 2 countries. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Sacramento, California

  • Pfizer Investigational Site

    San Francisco, California

  • Pfizer Investigational Site

    San Francisco, California

  • Pfizer Investigational Site

    San Francisco, California

  • Pfizer Investigational Site

    Auroa, Colorado

  • Pfizer Investigational Site

    Aurora, Colorado

  • Pfizer Investigational Site

    Washington D.C., District of Columbia

  • Pfizer Investigational Site

    Tampa, Florida

  • Pfizer Investigational Site

    Tampa, Florida

  • Pfizer Investigational Site

    Vero Beach, Florida

  • Pfizer Investigational Site

    Atlanta, Georgia

  • Pfizer Investigational Site

    New Orleans, Louisiana

  • Pfizer Investigational Site

    Santa Fe, New Mexico

  • Pfizer Investigational Site

    New York, New York

  • Pfizer Investigational Site

    Rochester, New York

  • Pfizer Investigational Site

    The Bronx, New York

  • Pfizer Investigational Site

    Cincinnati, Ohio

  • Pfizer Investigational Site

    Portland, Oregon

  • Pfizer Investigational Site

    Austin, Texas

  • Pfizer Investigational Site

    Annandale, Virginia

  • Pfizer Investigational Site

    Vancouver, British Columbia, Canada

  • Pfizer Investigational Site

    Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.